Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air, Inc. (XAIR) ten percent owner Lin Yi-Chien purchased 2,607 shares of common stock on October 13, 2026, at $2.21 per share. The transaction was reported as a direct purchase; reported direct holdings after it were 148,000 shares. No Rule 10b5-1 plan is reported.
Beyond Air, Inc. (XAIR) announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, its highest quarterly revenue reported. The company said revenue increased approximately 30% from the quarter ended June 30, 2026 and 27% from the same quarter last year, reflecting continued adoption of first-generation LungFit PH.
Beyond Air reaffirmed revenue guidance of $8 million for calendar 2026, excluding second-generation LungFit PH revenue, and $16 million to $18 million for calendar 2027, which includes anticipated revenue from the second-generation system, pending FDA approval. That system remains under FDA review. The quarterly estimate is based on management’s preliminary estimates and information available as of October 8, 2026; it is subject to completion of financial closing procedures and review of interim financial statements. The independent registered public accounting firm has not audited, reviewed or performed procedures on the preliminary figure, and actual revenue may differ materially. Beyond Air expects to report complete quarterly results in November 2026.
Beyond Air, Inc. (XAIR) ten percent owner Lin Yi-Chien reported three direct purchases totaling 20,393 shares of common stock: 15,393 on October 1, 2026, at a $2.80 weighted-average price; 2,000 on September 30 at $2.71; and 3,000 on September 29 at $2.69. Each reported price is a weighted average; the underlying purchases were at prices ranging from $2.67 to $2.85, inclusive. No Rule 10b5-1 plan is reported.
Beyond Air, Inc. (XAIR) is identified in a Form 3 showing ten percent owner Lin Yi-Chien’s direct holding of 125,000 shares of Common Stock as of September 28, 2026.
Beyond Air, Inc. (XAIR) common stock is the subject of Yi-Chien Lin’s reported beneficial ownership of 145,393 shares, equal to 14.8% of the class. Lin reported sole voting power and sole dispositive power over 145,393 shares.
Beyond Air, Inc. entered into an employment agreement with Chief Executive Officer Robert Goodman, effective September 23, 2026; he will continue reporting to the Board. The agreement has no fixed term and sets annual base salary at not less than $650,000, a 60% target annual bonus and a potential payout of 0% to 150% of target based on management objectives.
For termination without Cause (other than death or Disability) or resignation for Good Reason, terms provide accrued base salary, benefits and earned unpaid bonus, 12 months of salary continuation and COBRA premium reimbursement for 12 months, subject to timely election. If termination occurs from three months before through 12 months after a Change in Control, salary is paid in a lump sum equal to 24 months of base salary and COBRA reimbursement extends to 18 months. CFO Daniel Moorhead’s annual base salary increased from $325,000 to $463,000, effective September 23, 2026.
Beyond Air, Inc. (XAIR) has filed a resale prospectus covering up to 5,417,538 shares of common stock that may be offered from time to time by selling stockholders. The registered shares consist of 167,011 outstanding shares plus shares issuable upon exercise of pre-funded, Series A and Series B warrants issued in a July 29, 2026 private placement.
Beyond Air is not selling shares in this offering and will not receive proceeds from resales, though it will receive cash if warrants are exercised. The July 31, 2026 private placement raised ~$10.2 million in gross proceeds at combined prices of $5.66–$5.76 per share (or pre-funded warrant) plus common warrants.
The company recently effected a 1-for-20 reverse stock split effective July 13, 2026 to regain Nasdaq bid-price compliance; it is now under a one-year Nasdaq discretionary panel monitor, and future listing deficiencies during this period could lead to an accelerated delisting process. Common shares outstanding were 755,549 as of July 28, 2026 and would be 6,173,087 if all new warrants are fully exercised.
Beyond Air, Inc. (XAIR) reported results for the quarter ended June 30, 2026 and provided a corporate update. Revenue was $1.8 million, roughly flat year over year, while gross margin improved to 13% from 9%. Net loss attributable to common stockholders was $7.9 million, or $11.00 per share, compared with a loss of $7.7 million, or $30.67 per share, a year earlier.
As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled $15.2 million, against $22.2 million of long-term debt and total liabilities of $30.1 million, leaving stockholders’ equity at $2.8 million. After quarter-end, the company completed an up to $30.1 million financing, including $10.2 million in upfront gross proceeds and up to an additional $20.0 million from potential warrant exercises. Management reaffirmed revenue guidance of $8 million for calendar 2026 and $16–$18 million for 2027, and highlighted ongoing FDA review of a PMA supplement for its second-generation LungFit PH system, with approval expected in the second half of 2026.
Beyond Air, Inc. is registering for resale up to 5,417,538 shares of common stock for selling stockholders. The Shares consist of 167,011 issued shares plus shares issuable from Pre-Funded, Series A, and Series B Warrants. Beyond Air is not selling shares in this offering and will not receive proceeds from resales, though it may receive cash if warrants are exercised, which it expects to use for general working capital.
The Shares stem from a July 29, 2026 securities purchase agreement and a July 31, 2026 private placement that generated $10.2 million in gross proceeds at prices near market. Pre-Funded Warrants are exercisable at $0.0001 per share; Series A and B Warrants at $5.51 per share, subject to 4.99%–19.99% beneficial ownership limits. Common stock outstanding was 755,549 shares as of July 28, 2026, and would be 6,173,087 shares if all new warrants are exercised.
The company completed a 1-for-20 reverse stock split effective July 13, 2026 to address prior Nasdaq bid-price noncompliance and is now under a one-year Discretionary Panel Monitor. Beyond Air is a commercial-stage company marketing its FDA- and CE-marked LungFit® PH nitric oxide system and developing additional NO-based respiratory, oncology and neurology programs.